Daiichi Sankyo
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Daiichi Sankyo sits in the top decile of US sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count).
Daiichi Sankyo: 236 sponsored US clinical trials, 29 recruiting.
Daiichi Sankyo sponsors 236 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 167 completed. 71 of these trials are in Phase 3-4 (later-stage) and 153 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 7 trials.
Top-decile sponsor footprint
Daiichi Sankyo ranks in the top decile of sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 189 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
236 total, page 3 of 5
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
NCT02496884
Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers
NCT03699774
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
NCT02371369
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
NCT02234583
Treatment of Pain Associated With Fibromyalgia
NCT02187471
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
NCT02319369
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
NCT02303431
Treatment of Pain Associated With Fibromyalgia
NCT02187159
Treatment of Pain Associated With Fibromyalgia
NCT02146430
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
NCT02039726
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
NCT02150733
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
NCT02072434
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
NCT02134015
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
NCT02076451
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
NCT01826448
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
NCT02047565
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
NCT01956305
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
NCT02004678
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT01790503
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
NCT01877382
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
NCT01957280
Edoxaban in Peripheral Arterial Disease
NCT01802775
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
NCT01755767
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
NCT01756898
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
NCT01502631
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
NCT01662908
Effect of Tivantinib on the QTC Interval in Cancer Subjects
NCT01699061
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
NCT01499043
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
NCT01525602
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
NCT01588678
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
NCT01468467
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01565668
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
NCT01587651
Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke
NCT01496885
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
NCT01349036
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
NCT01517399
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT01496365
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT01349049
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT01390337
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
NCT01364844
A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus
NCT01862939
A Study of DS-2248 in Participants With Advanced Solid Tumors
NCT01288430
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
NCT01217229
Colesevelam for Children With Type 2 Diabetes
NCT01258075
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
NCT01244191
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
NCT01290471
Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
NCT01287858
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
NCT01260584
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
NCT01211483
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
NCT01033240
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 90 |
| Phase 2 | 63 |
| Phase 3 | 50 |
| Phase 4 | 21 |
What is open in the Daiichi Sankyo pipeline
29 recruiting of 236 indexed (12% open); 167 completed (71%).
Phase mix: 71 late (III/IV) vs 153 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Daiichi Sankyo: open-pipeline peers nationwide
Peers matched on 236 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Daiichi Sankyo sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 236 trials (± recruiting share)
- Loma Linda University · 237 trials · 15% recruiting
- Henry Ford Health System · 234 trials · 18% recruiting
- Incyte Corporation · 239 trials · 15% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 12% open enrollment (± trial volume)
- University of Iowa · 12% recruiting · 228 trials
- Augusta University · 12% recruiting · 106 trials
- National Institute of Mental Health (NIMH) · 12% recruiting · 343 trials
- National Heart, Lung, and Blood Institute (NHLBI) · 12% recruiting · 501 trials
Related
What to do with this Daiichi Sankyo page
236 registered trials is a research-attention snapshot, not an endorsement of Daiichi Sankyo or any single study.
- 29 of Daiichi Sankyo's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition Daiichi Sankyo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Daiichi Sankyo pipeline card: 236 registered trials from official public datasets.Report a data error.